Long-term blood pressure control: What can we do?

Postgraduate Medicine

Volumn 123, Issue 1, 2011, Pages 88-93

  Neutel, Joel M ^a  

^a Orange County Research Center   (United States)

Author keywords

Blood pressure; Combination therapy; Hypertension

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE PLUS TELMISARTAN; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS OLMESARTAN; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RAMIPRIL; TELMISARTAN; ANTIHYPERTENSIVE AGENT;

ANGIONEUROTIC EDEMA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; COUGHING; DRUG DOSE TITRATION; DRUG TOLERABILITY; GENERAL PRACTITIONER; HEALTH CARE COST; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY DISEASE; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; PATIENT COMPLIANCE; STROKE; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79952798589     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.01.2249     Document Type: Article

References (44)

1. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913.
3. Writing Group Members; Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215.
4. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49(1):69-75.
5. Steinberg BA, Bhatt DL, Mehta S, et al. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J. 2008;156(4):719-727.
6. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43(1):10-17.
7. Borzecki AM, Oliveria SA, Berlowitz DR. Barriers to hypertension control. Am Heart J. 2005;149(5):785-794.
8. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med.2005;353(5):487-497.
9. Muszbek N, Brixner D, Benedict A, et al. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract. 2008;62(2):338-351.
10. Erkens JA, Panneman MJ, Klungel OH, van den Boom G, Prescott MF, Herings RM. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf. 2005;14(11):795-803.
11. Siiskonen SJ, Breekveldt-Postma NS, Vincze G, Khan ZM, Erkens JA, Herings RM. Higher persistence with valsartan compared with enalapril in daily practice. Vasc Health Risk Manage. 2007;3(6):1039-1044.
12. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328(13):914-921.
13. Mancia G, DeBaker G, Dominiczak A, et al; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC practice guidelines for the management of arterial hypertension. J Hypertens.2007;25(9):1751-1762.
14. Chrysant SG. Fixed low-dose drug combination for the treatment of hypertension. Arch Fam Med. 1998;7(4):370-376.
15. FH. Combination therapy in hypertension. J Hum Hypertens.1992;6(suppl 2):19S-21S.
16. Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med.1996;156(17):1969-1978.
17. Sica DA. Fixed-dose combination anti-hypertensive drugs. Do they have a role in rational therapy? Drugs. 1994;48(1):16-24.
18. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-719.
19. Yusuf S, Teo KK, Pogue J, et al; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-1559.
20. Cohn JN, Goldman JM. Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy. Am J Hypertens. 2008;21(3):248-256.
21. Mason RP. A rationale for combination therapy in risk factor management: a mechanistic perspective. Am J Med. 2005;118(suppl 12A):54-61.
22. Siragy HM, Xue C, Webb RL. Beneficial effects of combined benazeprilamlodipine on cardiac nitric oxide, cGMP, and TNF-alpha production after cardiac ischemia. J Cardiovasc Pharmacol. 2006;47(5):636-642.
23. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation. 1998;97(6):576-580.
24. Neutel JM, Smith DH, Weber MA. Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens. 2004;17(1):37-42.
25. Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428.
26. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174-1183.
27. Chrysant SG. Amlodipine/ARB fixed-dose combinations for the treatment of hypertension: focus on amlodipine/olmesartan combination. Drugs Today (Barc). 2008;44(6):443-453.
28. Braun N, Ulmer HJ, Ansari A, Handrock R, Klebs S. Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination. Curr Med Res Opin.2009;25(2):421-430.
29. Littlejohn TW 3rd, Majul CR, Olvera R, et al; study investigators. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 × 4 factorial study. Postgrad Med.2009;121(2):5-14.
30. Littlejohn T 3rd, Chrysant SG, Neutel J, et al; study investigators. Combination of telmisartan with amlodipine provides an effective treatment option for elderly patients: sub-analysis from a factorial design study. Poster presented at: 24th Annual Scientific Meeting of the American Society of Hypertension; May 6-9, 2009; San Francisco, CA.
31. Littlejohn T 3rd, Punzi H, Serfer G, et al; study investigators. Efficacy of telmisartan in combination with amlodipine in hypertensive patients from Latin and North America: sub-analysis from a factorial design study. Poster presented at: 24th Annual Scientific Meeting of the American Society of Hypertension; May 6-9, 2009; San Francisco, CA.
32. Littlejohn T 3rd, Punzi H, Webster D, et al; study investigators. Telmisartan plus amlodipine combination is effective in both treatment-naïve and previously treated hypertensive patients: sub-analysis from a factorial design study. Poster presented at: 24th Annual Scientific Meeting of the American Society of Hypertension; May 6-9, 2009; San Francisco, CA.
33. Littlejohn T 3rd, Graff A, Punzi H, et al; study investigators. Efficacy of telmisartan in combination with amlodipine in hypertensive patients according to race: sub-analysis from a factorial design study. Poster presented at: 24th Annual Scientific Meeting of the American Society of Hypertension; May 6-9, 2009; San Francisco, CA.
34. Littlejohn T 3rd, Guthrie R, Neutel J, et al; study investigators. Telmisartan and amlodipine in combination are effective at lowering 24-hour BP in black and Latin American hypertensive patients: findings of an ABPM substudy. Poster presented at: 24th Annual Scientific Meeting of the American Society of Hypertension; May 6-9, 2009; San Francisco, CA.
35. Littlejohn T 3rd, Chrysant SG, Webster D, et al; study investigators. Efficacy of telmisartan in combination with amlodipine in obese hypertensive patients: sub-analysis from a factorial design study. Poster presented at: 24th Annual Scientific Meeting of the American Society of Hypertension; May 6-9, 2009; San Francisco, CA.
36. Neutel JM. Prescribing patterns in hypertension: the emerging role of fixed dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin. 2008;24(8):2389-2401.
37. Vawter L, Tong X, Gemilyan M, Yoon PW. Barriers to antihypertensive medication adherence among adults-United States, 2005. J Clin Hypertens (Greenwich). 2008;10(12):922-929.
38. Burnier M, Brown RE, Ong SH, Keskinaslan A, Khan ZM. Issues in blood pressure control and the potential role of single-pill combination therapies. Int J Clin Pract. 2009;63(5):790-798.
39. Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SA, Feagan BG. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension.2009;53(4):646-653.
40. Düsing R, Handrock R, Klebs S, Tousset E, Vrijens B. Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE. J Hypertens. 2009;27(4):894-901.
41. Stankus V, Hemmelgarn B, Campbell NR, Chen G, McAlister FA, Tsuyuki RT. Reducing costs and improving hypertension management. Can J Clin Pharmacol. 2009;16(1):151e-155e.
42. Moser M. From JNC1 to JNC7-what have we learned? Prog Cardiovasc Dis. 2006;48(5):303-315.
43. Julius S, Kjeldsen SE, Weber M, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet.2004;363(9426):2022-2031.
44. Krousel-Wood MA, Muntner P, Islam T, Morisky DE, Webber LS. Barriers to and determinants of medication adherence in hypertension management: perspective of the cohort study of medication adherence among older adults. Med Clin North Am. 2009;93(3):753-769.